1
|
Pollard SM, Yoshikawa K, Clarke ID, Danovi
D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, et
al: Glioma stem cell lines expanded in adherent culture have
tumor-specific phenotypes and are suitable for chemical and genetic
screens. Cell Stem Cell. 4:568–580. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Paolillo M, Serra M and Schinelli S:
Integrins in glioblastoma: Still an attractive target? Pharmacol
Res. 113A:55–61. 2016. View Article : Google Scholar
|
3
|
Russo MA, Paolillo M, Sanchez-Hernandez Y,
Curti D, Ciusani E, Serra M, Colombo L and Schinelli S: A
small-molecule RGD-integrin antagonist inhibits cell adhesion, cell
migration and induces anoikis in glioblastoma cells. Int J Oncol.
42:83–92. 2013. View Article : Google Scholar :
|
4
|
Panzeri S, Zanella S, Arosio D, Vahdati L,
Dal Corso A, Pignataro L, Paolillo M, Schinelli S, Belvisi L,
Gennari C, et al: Cyclic isoDGR and RGD peptidomimetics containing
bifunctional diketopiperazine scaffolds are integrin antagonists.
Chemistry. 21:6265–6271. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Cheng NC, van Zandwijk N and Reid G:
Cilengitide inhibits attachment and invasion of malignant pleural
mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
PLoS One. 9:e903742014. View Article : Google Scholar
|
6
|
Mikheev AM, Mikheeva SA, Trister AD,
Tokita MJ, Emerson SN, Parada CA, Born DE, Carnemolla B, Frankel S,
Kim DH, et al: Periostin is a novel therapeutic target that
predicts and regulates glioma malignancy. Neuro-oncol. 17:372–382.
2015. View Article : Google Scholar :
|
7
|
Arosio D, Belvisi L, Colombo L, Colombo M,
Invernizzi D, Manzoni L, Potenza D, Serra M, Castorina M, Pisano C,
et al: A potent integrin antagonist from a small library of cyclic
RGD pentapeptide mimics including benzyl-substituted
azabicycloalkane amino acids. ChemMedChem. 3:1589–1603. 2008.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Carra E, Barbieri F, Marubbi D, Pattarozzi
A, Favoni RE, Florio T and Daga A: Sorafenib selectively depletes
human glioblastoma tumor-initiating cells from primary cultures.
Cell Cycle. 12:491–500. 2013. View
Article : Google Scholar : PubMed/NCBI
|
9
|
Lee KH, Ahn EJ, Oh SJ, Kim O, Joo YE, Bae
JA, Yoon S, Ryu HH, Jung S, Kim KK, et al: KITENIN promotes glioma
invasiveness and progression, associated with the induction of EMT
and stemness markers. Oncotarget. 6:3240–3253. 2015.PubMed/NCBI
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Δ Δ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
11
|
Hadjimichael C, Chanoumidou K,
Papadopoulou N, Arampatzi P, Papamatheakis J and Kretsovali A:
Common stemness regulators of embryonic and cancer stem cells.
World J Stem Cells. 7:1150–1184. 2015.PubMed/NCBI
|
12
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: Biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View
Article : Google Scholar
|
13
|
Silginer M, Weller M, Ziegler U and Roth
P: Integrin inhibition promotes atypical anoikis in glioma cells.
Cell Death Dis. 5:e10122014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Mizushima N and Yoshimori T: How to
interpret LC3 immunob-lotting. Autophagy. 3:542–545. 2007.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Seguin L, Desgrosellier JS, Weis SM and
Cheresh DA: Integrins and cancer: Regulators of cancer stemness,
metastasis, and drug resistance. Trends Cell Biol. 25:234–240.
2015. View Article : Google Scholar : PubMed/NCBI
|
16
|
Buchheit CL, Weigel KJ and Schafer ZT:
Cancer cell survival during detachment from the ECM: Multiple
barriers to tumour progression. Nat Rev Cancer. 14:632–641. 2014.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Beier D, Schulz JB and Beier CP:
Chemoresistance of glioblastoma cancer stem cells--much more
complex than expected. Mol Cancer. 10:1282011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Cosset É, Ilmjärv S, Dutoit V, Elliott K,
von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez
G, et al: Glut3 addiction is a druggable vulnerability for a
molecularly defined subpopulation of glioblastoma. Cancer Cell.
32:856–868.e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
19
|
Christmann M, Diesler K, Majhen D,
Steigerwald C, Berte N, Freund H, Stojanović N, Kaina B, Osmak M,
Ambriović-Ristov A, et al: Integrin αVβ3 silencing sensitizes
malignant glioma cells to temozolomide by suppression of homologous
recombination repair. Oncotarget. 8:27754–27771. 2017. View Article : Google Scholar
|
20
|
Rahman M, Reyner K, Deleyrolle L, Millette
S, Azari H, Day BW, Stringer BW, Boyd AW, Johns TG, Blot V, et al:
Neurosphere and adherent culture conditions are equivalent for
malignant glioma stem cell lines. Anat Cell Biol. 48:25–35. 2015.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Lange SC, Bak LK, Waagepetersen HS,
Schousboe A and Norenberg MD: Primary cultures of astrocytes: Their
value in understanding astrocytes in health and disease. Neurochem
Res. 37:2569–2588. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Malik N, Wang X, Shah S, Efthymiou AG, Yan
B, Heman-Ackah S, Zhan M and Rao M: Comparison of the gene
expression profiles of human fetal cortical astrocytes with
pluripotent stem cell derived neural stem cells identifies human
astrocyte markers and signaling pathways and transcription factors
active in human astrocytes. PLoS One. 9:e961392014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Lundin A, Delsing L, Clausen M, Ricchiuto
P, Sanchez J, Sabirsh A, Ding M, Synnergren J, Zetterberg H, Brolén
G, et al: Human iPS-derived astroglia from a stable neural
precursor state show improved functionality compared with
conventional astrocytic models. Stem Cell Reports. 10:1030–1045.
2018. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhang Y, Sloan SA, Clarke LE, Caneda C,
Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MS, Li G,
et al: Purification and characterization of progenitor and mature
human astrocytes reveals transcriptional and functional differences
with mouse. Neuron. 89:37–53. 2016. View Article : Google Scholar :
|
25
|
Lee J, Kotliarova S, Kotliarov Y, Li A, Su
Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al:
Tumor stem cells derived from glioblastomas cultured in bFGF and
EGF more closely mirror the phenotype and genotype of primary
tumors than do serum-cultured cell lines. Cancer Cell. 9:391–403.
2006. View Article : Google Scholar : PubMed/NCBI
|
26
|
Leblond P, Dewitte A, Le Tinier F,
Bal-Mahieu C, Baroncini M, Sarrazin T, Lartigau E, Lansiaux A and
Meignan S: Cilengitide targets pediatric glioma and neuroblastoma
cells through cell detachment and anoikis induction. Anticancer
Drugs. 24:818–825. 2013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Oliveira-Ferrer L, Hauschild J, Fiedler W,
Bokemeyer C, Nippgen J, Celik I and Schuch G: Cilengitide induces
cellular detachment and apoptosis in endothelial and glioma cells
mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer
Res. 27:862008. View Article : Google Scholar : PubMed/NCBI
|
28
|
Antonioli M, Di Rienzo M, Piacentini M and
Fimia GM: Emerging mechanisms in initiating and terminating
autophagy. Trends Biochem Sci. 42:28–41. 2017. View Article : Google Scholar
|
29
|
Bianconi D, Unseld M and Prager GW:
Integrins in the spotlight of cancer. Int J Mol Sci. 17:2037–2064.
2016. View Article : Google Scholar
|
30
|
Xia H, Nho RS, Kahm J, Kleidon J and Henke
CA: Focal adhesion kinase is upstream of phosphatidylinositol
3-kinase/ Akt in regulating fibroblast survival in response to
contraction of type I collagen matrices via a beta 1 integrin
viability signaling pathway. J Biol Chem. 279:33024–33034. 2004.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Beauséjour M, Thibodeau S, Demers MJ,
Bouchard V, Gauthier R, Beaulieu JF and Vachon PH: Suppression of
anoikis in human intestinal epithelial cells: Differentiation
state-selective roles of α2β1, α3β1, α5β1, and α6β4 integrins. BMC
Cell Biol. 14:532013. View Article : Google Scholar
|
32
|
Alanko J, Mai A, Jacquemet G, Schauer K,
Kaukonen R, Saari M, Goud B and Ivaska J: Integrin endosomal
signalling suppresses anoikis. Nat Cell Biol. 17:1412–1421. 2015.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Niola F, Zhao X, Singh D, Sullivan R,
Castano A, Verrico A, Zoppoli P, Friedmann-Morvinski D, Sulman E,
Barrett L, et al: Mesenchymal high-grade glioma is maintained by
the ID-RAP1 axis. J Clin Invest. 123:405–417. 2013. View Article : Google Scholar :
|
34
|
Platten M, Wick W, Wild-Bode C, Aulwurm S,
Dichgans J and Weller M: Transforming growth factors beta(1)
(TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via
Up-regulation of alpha(V)beta(3) integrin expression. Biochem
Biophys Res Commun. 268:607–611. 2000. View Article : Google Scholar : PubMed/NCBI
|
35
|
Parvani JG, Galliher-Beckley AJ, Schiemann
BJ and Schiemann WP: Targeted inactivation of β1 integrin induces
β3 integrin switching, which drives breast cancer metastasis by
TGF-β. Mol Biol Cell. 24:3449–3459. 2013. View Article : Google Scholar : PubMed/NCBI
|